Acute otitis media: Influence of the PCV-7 vaccine on changes in the disease and its management

Journal of Family Practice

Volumn 54, Issue 11, 2005, Pages 961-968

  Brunton, Stephen ^a   Pichichero, Michael E ^b  

^a AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTIBUTEN; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COTRIMOXAZOLE; LORACARBEF; PEDIAZOLE; PNEUMOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE PCV 7; UNCLASSIFIED DRUG;

DOSE TIME EFFECT RELATION; DRUG MEGADOSE; HAEMOPHILUS INFLUENZAE; HUMAN; OTITIS MEDIA; PATIENT COMPLIANCE; RECURRENT DISEASE; REVIEW; TASTE PREFERENCE; VACCINATION;

ACUTE DISEASE; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; UNITED STATES;

EID: 27744596655     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22:10-16.
2. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
3. Block SL, Harrison CH, Hedrick J, et al. Restricted use of antibiotic prophylaxis for recurrent acute otitis media in the era of penicillin non-susceptible Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol. 2001;61:47-60.
4. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-9):1-35.
5. American Academy of Family Physicians Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.
6. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:1-9.
7. Block SL. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J. 1997;16:449-456.
8. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J. 1992;11(suppl 8):S7-S11.
9. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829-833.
10. Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828.
11. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:177-178.
12. Centers for Disease Control and Prevention. Pneumococcal conjugate vaccine shortage resolved. MMWR Morb Mortal Wkly Rep. 2004;53:851-852.
13. Prevnar® (pneumococcal 7-valent vaccine) [prescribing information]. Philadelphia, Pa: Wyeth Pharmaceuticals. Rev. 01/04.
14. Watson W. Pneumococcal conjugate vaccines. Pediatr Infect Dis J. 2000;19:331-332.
15. Giebink GS. The prevention of pneumococcal disease in children. N Engl J Med. 2001;345:1177-1183.
16. Pelton SI, Loughlin AM, Marchand CD. Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J. 2003;23:1015-1022.
17. Freed GL, Davis MM, Clark SJ. Variation in public and private supply of pneumococcal conjugate vaccine during a shortage. JAMA. 2003;289:575-578.
18. Centers for Disease Control and Prevention. Decreased availability of pneumococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2001;50:783-784.
19. Centers for Disease Control and Prevention. Limited supply of pneumococcal conjugate vaccine: suspension of recommendation for fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:108-109.
20. CDC National Immunization Survey. Estimated vaccination coverage with individual vaccines and selected vaccination series by 24 months of age by state and immunization action plan area US, Q3/2003-Q4/2004. Available at: http://www2a.cdc.gov/nip/coverage/nis/nis_iap.asp?fmt=v&rpt= tab09_24mo_iap_0304&qtr=Q3/2003-Q2/2004. Accessed September 20, 2005.
21. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-1746.
22. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004;23:485-489.
23. Pichichero ME, Casey JR. Acute otitis media: Making sense of recent guidelines on antimicrobial treatment. J Fam Pract. 2005;54:313-332.
24. Block SL, Harrison CJ. Diagnosis and Management of Acute Otitis Media, 3rd ed. In press.